In the MIROCALS trial, Gilbert Bensimon and colleagues1 showed that low-dose interleukin-2 (IL-2) added to riluzole did not significantly reduce mortality in an unadjusted analysis of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback